BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 3030201)

  • 1. Cytomegalovirus as a risk factor in living-related renal transplantation. A prospective study.
    Pollak R; Barber PL; Prusak BF; Mozes MF
    Ann Surg; 1987 Mar; 205(3):302-4. PubMed ID: 3030201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation.
    Weir MR; Henry ML; Blackmore M; Smith J; First MR; Irwin B; Shen S; Genemans G; Alexander JW; Corry RJ
    Transplantation; 1988 Jan; 45(1):111-6. PubMed ID: 2827352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation.
    Smiley ML; Wlodaver CG; Grossman RA; Barker CF; Perloff LJ; Tustin NB; Starr SE; Plotkin SA; Friedman HM
    Transplantation; 1985 Aug; 40(2):157-61. PubMed ID: 2992130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
    Lewis RM; Johnson PC; Golden D; Van Buren CT; Kerman RH; Kahan BD
    Transplantation; 1988 Feb; 45(2):353-9. PubMed ID: 2830686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppression.
    Johnson PC; Lewis RM; Golden DL; Oefinger PE; Van Buren CT; Kerman RH; Kahan BD
    Transplantation; 1988 Jan; 45(1):116-21. PubMed ID: 2827353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of CMV infection by screening for CMV antibodies in renal allograft recipients and their blood and kidney donors.
    Metselaar HJ; Ploeg RJ; Van Loon AM; Weiland HT; Rothbarth PH; Paul LC; Brand A; Schaafsma R; Hendriks GF; Jeekel J
    Scand J Infect Dis; 1988; 20(2):135-9. PubMed ID: 2840730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of donor factors other than serologic status on transmission of cytomegalovirus to transplant recipients.
    Chou SW; Norman DJ
    Transplantation; 1988 Jul; 46(1):89-93. PubMed ID: 2839917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transplanted kidney as a source of cytomegalovirus infection.
    Ho M; Suwansirikul S; Dowling JN; Youngblood LA; Armstrong JA
    N Engl J Med; 1975 Nov; 293(22):1109-12. PubMed ID: 171567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus.
    Grundy JE; Lui SF; Super M; Berry NJ; Sweny P; Fernando ON; Moorhead J; Griffiths PD
    Lancet; 1988 Jul; 2(8603):132-5. PubMed ID: 2899189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus infection and graft rejection in renal transplantation.
    Dickenmann MJ; Cathomas G; Steiger J; Mihatsch MJ; Thiel G; Tamm M
    Transplantation; 2001 Mar; 71(6):764-7. PubMed ID: 11330539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
    Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
    Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants.
    Marker SC; Howard RJ; Simmons RL; Kalis JM; Connelly DP; Najarian JS; Balfour HH
    Surgery; 1981 Jun; 89(6):660-71. PubMed ID: 6264640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: implications for donor selection.
    Schnitzler MA; Woodward RS; Brennan DC; Spitznagel EL; Dunagan WC; Bailey TC
    Surgery; 1997 May; 121(5):563-8. PubMed ID: 9142156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral infections in renal transplant donors and their recipients: a prospective study.
    Balfour HH; Slade MS; Kalis JM; Howard RJ; Simmons RL; Najarian JS
    Surgery; 1977 May; 81(5):487-92. PubMed ID: 191948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity.
    Weir MR; Irwin BC; Maters AW; Genemans G; Shen SY; Charache P; Williams GM
    Transplantation; 1987 Feb; 43(2):187-93. PubMed ID: 3027930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
    Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
    J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
    Vincenti F; Budde K; Merville P; Shihab F; Ram Peddi V; Shah M; Wyburn K; Cassuto-Viguier E; Weidemann A; Lee M; Flegel T; Erdman J; Wang X; Lademacher C
    Am J Transplant; 2018 Dec; 18(12):2945-2954. PubMed ID: 29745007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses.
    Toupance O; Bouedjoro-Camus MC; Carquin J; Novella JL; Lavaud S; Wynckel A; Jolly D; Chanard J
    Transpl Int; 2000; 13(6):413-9. PubMed ID: 11140239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.